2.26 USD
▲0.00+2.73%
盘后 2.24 +1.82%
2026-08-03
市值
$142.89M
市盈率
—
EPS
-0.26
股息率
—
52 周区间
0.46 – 3.54
成交量
438.53K
Beta
1.81
目标价
8.56
52W 低 0.4652W 高 3.54
价格走势
公司简介
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its n...